Scientific recommendation on classification of advanced therapy medicinal products


Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Autologous CD34+ cells transduced with a lentiviral vector encoding for the CD18 β-subunit of human β2 Integrin.

Brief description of the finished product

Autologous CD34+ cells transduced with a lentiviral vector encoding for the CD18 β-subunit of human β2 Integrin suspended in a bag for infusion.

Proposed indication

Treatment of severe leukocyte adhesion deficiency type I.

EMA/CAT conclusion

The procedure was finalised on 20 December 2018 for the following recommendation.
On the basis that:

- the product contains a biological medicinal product as the active substance;
- the active substance contains a recombinant nucleic acid administered to human beings with a view to adding a genetic sequence;
- its therapeutic effect relates directly to the product of the genetic expression of this sequence,

the EMA/CAT considers that the product falls within the definition of a gene therapy medicinal product, as provided in Article 2(1) of Regulation (EC) 1394/2007.